INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 186 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q3 2018. The put-call ratio across all filers is 0.99 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2020 | $10,211,000 | -23.9% | 213,137 | 0.0% | 0.00% | -50.0% |
| Q1 2020 | $13,419,000 | -49.2% | 213,137 | 0.0% | 0.00% | -33.3% |
| Q4 2019 | $26,412,000 | +86.7% | 213,137 | 0.0% | 0.01% | +100.0% |
| Q3 2019 | $14,144,000 | -16.6% | 213,137 | 0.0% | 0.00% | -25.0% |
| Q2 2019 | $16,959,000 | -28.9% | 213,137 | 0.0% | 0.00% | -33.3% |
| Q1 2019 | $23,842,000 | +11.0% | 213,137 | 0.0% | 0.01% | 0.0% |
| Q4 2018 | $21,482,000 | -20.2% | 213,137 | 0.0% | 0.01% | -14.3% |
| Q3 2018 | $26,932,000 | +50.6% | 213,137 | 0.0% | 0.01% | +75.0% |
| Q2 2018 | $17,884,000 | -76.6% | 213,137 | -82.9% | 0.00% | -76.5% |
| Q1 2018 | $76,578,000 | +12.6% | 1,244,759 | +7.0% | 0.02% | +13.3% |
| Q4 2017 | $67,987,000 | -36.8% | 1,163,759 | -37.2% | 0.02% | -37.5% |
| Q3 2017 | $107,604,000 | -53.8% | 1,853,959 | -3.7% | 0.02% | -56.4% |
| Q2 2017 | $233,115,000 | +3.8% | 1,925,459 | -3.0% | 0.06% | +1.9% |
| Q1 2017 | $224,499,000 | -3.6% | 1,984,959 | -7.4% | 0.05% | -8.5% |
| Q4 2016 | $232,778,000 | -31.6% | 2,142,459 | +3.7% | 0.06% | -33.0% |
| Q3 2016 | $340,201,000 | +16.1% | 2,066,959 | +0.6% | 0.09% | +11.4% |
| Q2 2016 | $293,059,000 | +20.4% | 2,053,959 | +8.4% | 0.08% | +17.9% |
| Q1 2016 | $243,317,000 | +3.9% | 1,893,959 | +20.8% | 0.07% | +3.1% |
| Q4 2015 | $234,112,000 | +0.0% | 1,567,537 | +11.1% | 0.06% | -5.8% |
| Q3 2015 | $234,018,000 | +24.3% | 1,410,937 | +80.9% | 0.07% | +35.3% |
| Q2 2015 | $188,276,000 | -14.4% | 780,000 | 0.0% | 0.05% | -13.6% |
| Q1 2015 | $219,976,000 | +180.4% | 780,000 | +55.1% | 0.06% | +181.0% |
| Q4 2014 | $78,446,000 | -55.0% | 502,858 | -31.8% | 0.02% | -57.1% |
| Q3 2014 | $174,393,000 | +0.0% | 736,800 | 0.0% | 0.05% | +2.1% |
| Q2 2014 | $174,349,000 | -47.4% | 736,800 | -26.7% | 0.05% | -48.9% |
| Q1 2014 | $331,357,000 | +1677.9% | 1,004,751 | +272.1% | 0.09% | +1466.7% |
| Q3 2013 | $18,638,000 | +3.9% | 270,000 | -32.5% | 0.01% | 0.0% |
| Q2 2013 | $17,936,000 | – | 400,000 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Carmignac Gestion | 2,028,192 | $229,389,000 | 1.76% |
| Orbimed Advisors | 1,037,000 | $117,285,000 | 1.33% |
| BB BIOTECH AG | 255,719 | $28,922,000 | 0.95% |
| ALTRINSIC GLOBAL ADVISORS LLC | 193,369 | $21,870,000 | 0.74% |
| FALCON POINT CAPITAL, LLC | 44,573 | $5,041,000 | 0.67% |
| Rhenman & Partners Asset Management AB | 30,000 | $3,393,000 | 0.54% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 11,155 | $1,262,000 | 0.48% |
| NATIONAL PLANNING CORP | 52,400 | $5,888,000 | 0.44% |
| HIGHFIELDS CAPITAL MANAGEMENT LP | 364,232 | $41,195,000 | 0.38% |
| SPHERA FUNDS MANAGEMENT LTD. | 15,000 | $1,697,000 | 0.33% |